Why is "Mineralocorticoid receptor antagonist" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-22 22:20:02
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Mineralocorticoid_receptor_antagonist entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-04-22 and was most recently seen on 2026-04-22.
Wikipedia Overview
A mineralocorticoid receptor antagonist or aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure. Spironolactone, the first member of the class, is also used in the management of hyperaldosteronism and female hirsutism. Most antimineralocorticoids, including spironolactone, are steroidal spirolactones. Finerenone is a nonsteroidal antimineralocorticoid.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Positioning esaxerenone, a non-steroidal mineralocorticoid receptor antagonist, in the treatment of hypertension with and without hemodynamic cardiac stress - Nature
-
A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity - American Heart Association Journals
-
A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist - Frontiers
-
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure: - JACC Journals
-
Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist - Cureus
-
Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients - onlinelibrary.wiley.com
-
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis - The Lancet
-
MRA Treatment Ups Hyperkalemia Risk, but Not Death in CKD - Renal and Urology News
-
Reduced risk of hyperkalemia with sacubitril/valsartan compared to enalapril in presence of mineralocorticoid receptor antagonist: The PARADIGM-HF trial - 2 Minute Medicine
-
Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis - American Heart Association Journals
-
Prenatal exposure to the mineralocorticoid receptor antagonist spironolactone disrupts hippocampal area CA2 connectivity and alters behavior in mice | Neuropsychopharmacology - Nature
-
A novel mineralocorticoid receptor antagonist, 7,3',4'-trihydroxyisoflavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids - Nature
-
A Randomized trial assessing Efficacy and safety of Mineralocorticoid receptor Antagonist therapy compared to Standard antihypertensive Therapy in hypErtension with low Renin (REMASTER): rationale and study design - Nature
-
Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases | Hypertension - American Heart Association Journals
-
Evaluating the effects of adrenalectomy and mineralocorticoid receptor antagonist on cardiac remodeling and diastolic function in patients with aldosterone-producing adenoma - Nature
-
Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis - Nature
-
Assessment of cardiovascular disease risk by plasma renin activity changes in patients with primary aldosteronism on mineralocorticoid receptor antagonist treatment - Nature
-
The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy - Nature
-
Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension - Nature
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes - NEJM
-
Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients - PharmaTimes
-
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist - Nature
-
Bayer introduces medication for Chronic Kidney Disease - expresspharma.in
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.